Abstract
Clinical evaluation of medicated bathing agent “Eaudeleman” is made in 67 patients with atopic dermatitis and 26 patients with asteatotic dermatitis for 4 weeks in a multicenter open trial study. In addition, 59 patients with atopic dermatitis and 25 patients with asteatotic dermatitis are also evaluated as a control group. No significant difference was found between the test group and the control group in the both diseases. The final global improvement rating was 65.7% (44/67) at the test group and 71.2% (43/59) at the control group in more than slight improvement in atopic patients, while it was 100.0% (26/26) at the test group and 88.0% (22/25) at the control group in asteatotic patients. The side effects were seen seven in patients with atopic dermatitis, and none in patients with asteatotic dermatitis.
| Original language | English |
|---|---|
| Pages (from-to) | 867-874 |
| Number of pages | 8 |
| Journal | [Hifu] Skin research |
| Volume | 36 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1994 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Dermatology
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Clinical Evaluation of Medicated Bathing Agent Eaudeleman in Patients with Atopic Dermatitis:Clinical Research Group of Medicated Bathing Agent Eaudeleman'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver